{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:52:55Z","timestamp":1794887575642,"version":"4.9.1"},"reference-count":102,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic myelogenous leukemia (CML) in children is relatively rare. Because of a lack of robust clinical study evidence, management of CML in children is not standardized and often follows guidelines developed for adults. Children and young adults tend to have a more aggressive clinical presentation than older adults, and prognostic scores for adult CML do not apply to children. CML in children has been considered to have the same biology as in adults, but recent data indicate that some genetic differences exist in pediatric and adult CML. Because children with CML may receive tyrosine kinase inhibitor (TKI) therapy for many decades, and are exposed to TKIs during a period of active growth, morbidities in children with CML may be distinct from those in adults and require careful monitoring. Aggressive strategies, such as eradication of CML stem cells with limited duration and intensive regimens of chemotherapy and TKIs, may be more advantageous in children as a way to avoid lifelong exposure to TKIs and their associated adverse effects. Blood and marrow transplantation in pediatric CML is currently indicated only for recurrent progressive disease, and the acute and long-term toxicities of this option should be carefully evaluated against the complications associated with lifelong use of TKIs.<\/jats:p>","DOI":"10.1182\/blood-2015-06-648667","type":"journal-article","created":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T23:15:48Z","timestamp":1446074148000},"page":"392-399","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":174,"title":["Pediatric chronic myeloid leukemia is a unique disease that requires a different approach"],"prefix":"10.1182","volume":"127","author":[{"given":"Nobuko","family":"Hijiya","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology\/Stem Cell Transplantation, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL;"},{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-6438","authenticated-orcid":false,"given":"Kirk R.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital and Child and Family Research Institute, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology and Hematology, Department of Paediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Millot","sequence":"additional","affiliation":[{"name":"Centre d\u2019Investigation Clinique 1402, INSERM, University Hospital Poitiers, Poitiers, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, University Children\u2019s Hospital, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111902573146500_B1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40265-014-0207-7","article-title":"First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies.","volume":"74","author":"Gugliotta","year":"2014","journal-title":"Drugs"},{"key":"2019111902573146500_B2"},{"issue":"1","key":"2019111902573146500_B3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions.","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"14","key":"2019111902573146500_B4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111902573146500_B5","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2019111902573146500_B6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111902573146500_B7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"2019111902573146500_B8","article-title":"NCCN Clinical Practice Guidelines in Oncology.","year":"2015"},{"issue":"11","key":"2019111902573146500_B9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111902573146500_B10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1542\/peds.2004-2473","article-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia.","volume":"116","author":"Millot","year":"2005","journal-title":"Pediatrics"},{"issue":"21","key":"2019111902573146500_B11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3741.3741","article-title":"The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): objectives and preliminary results [abstract].","volume":"120","author":"Millot","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111902573146500_B12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","article-title":"Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.","volume":"93","author":"Kalmanti","year":"2014","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111902573146500_B13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1600-0609.2008.01170.x","article-title":"Correlation of BCR\/ABL transcript variants with patients\u2019 characteristics in childhood chronic myeloid leukaemia.","volume":"82","author":"Adler","year":"2009","journal-title":"Eur J Haematol"},{"issue":"2","key":"2019111902573146500_B14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood.V77.2.324.324","article-title":"Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias.","volume":"77","author":"Suryanarayan","year":"1991","journal-title":"Blood"},{"issue":"11","key":"2019111902573146500_B15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/gcc.21989","article-title":"Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia.","volume":"51","author":"Krumbholz","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"2019111902573146500_B16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2141.2002.03508.x","article-title":"Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene.","volume":"117","author":"Branford","year":"2002","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111902573146500_B17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1365-2141.1998.00945.x","article-title":"A polymorphism in exon b2 of the major breakpoint cluster region (M-bcr) identified in chronic myeloid leukaemia patients.","volume":"103","author":"Meissner","year":"1998","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111902573146500_B18","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/sj.leu.2401929","article-title":"Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.","volume":"14","author":"Saussele","year":"2000","journal-title":"Leukemia"},{"issue":"9","key":"2019111902573146500_B19","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.V78.9.2407.2407","article-title":"BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia.","volume":"78","author":"Aurer","year":"1991","journal-title":"Blood"},{"issue":"1","key":"2019111902573146500_B20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cancergencyto.2006.01.015","article-title":"Childhood CML in India: b2a2 transcript is more common than b3a2.","volume":"169","author":"Hasan","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"issue":"10","key":"2019111902573146500_B21","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"2019111902573146500_B22","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2019111902573146500_B23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3324\/haematol.2009.019224","article-title":"Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.","volume":"95","author":"Suttorp","year":"2010","journal-title":"Haematologica"},{"issue":"7","key":"2019111902573146500_B24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"2019111902573146500_B25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients.","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"2019111902573146500_B26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00277-015-2367-2","article-title":"Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?","volume":"94","author":"Gurrea Salas","year":"2015","journal-title":"Ann Hematol"},{"issue":"15","key":"2019111902573146500_B27","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1182\/blood-2014-05-578567","article-title":"Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study.","volume":"124","author":"Millot","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111902573146500_B28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjh.13453","article-title":"Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.","volume":"170","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"key":"2019111902573146500_B29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/asheducation-2010.1.368","article-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation.","volume":"2010","author":"Suttorp","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"2019111902573146500_B30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12185-012-1010-4","article-title":"Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study.","volume":"95","author":"Mitra","year":"2012","journal-title":"Int J Hematol"},{"issue":"1","key":"2019111902573146500_B31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","article-title":"Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period.","volume":"96","author":"Savage","year":"1997","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111902573146500_B32","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2019111902573146500_B33","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children\u2019s Oncology Group phase 1 study.","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111902573146500_B34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.23031","article-title":"Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children\u2019s Oncology Group.","volume":"57","author":"Champagne","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"2019111902573146500_B35","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111902573146500_B36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.2010.30.7231","article-title":"Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children\u2019s oncology group phase I consortium.","volume":"29","author":"Aplenc","year":"2011","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111902573146500_B37","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","article-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.","volume":"31","author":"Zwaan","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111902573146500_B38","doi-asserted-by":"crossref","article-title":"A phase 2 study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to imatinib.","author":"Zwaan","DOI":"10.1200\/jco.2012.30.15_suppl.tps9594"},{"issue":"4","key":"2019111902573146500_B39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.bloodjournal634789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia.","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"3","key":"2019111902573146500_B40","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111902573146500_B41","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.bloodjournal6661352","article-title":"Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation.","volume":"66","author":"Sokal","year":"1985","journal-title":"Blood"},{"issue":"9","key":"2019111902573146500_B42","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2019111902573146500_B43","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate.","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111902573146500_B44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1210\/jc.2012-2426","article-title":"Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.","volume":"98","author":"Vandyke","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019111902573146500_B45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-0033-1343483","article-title":"TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.","volume":"225","author":"Ulmer","year":"2013","journal-title":"Klin Padiatr"},{"issue":"21","key":"2019111902573146500_B46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3984.3984","article-title":"Cardiac failure in juvenile rats caused by continuous long-term exposure to the tyrosine kinase inhibitor dasatinib can be circumvented by an intermittent application schedule [abstract].","volume":"122","author":"Geidel","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111902573146500_B47","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pbc.24121","article-title":"Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.","volume":"59","author":"Rastogi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111902573146500_B48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pbc.22945","article-title":"Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.","volume":"56","author":"Hobernicht","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2019111902573146500_B49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia.","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2019111902573146500_B50","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3324\/haematol.2009.008359","article-title":"Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.","volume":"94","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"issue":"9633","key":"2019111902573146500_B51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(08)61023-5","article-title":"Low bone density and decreased inhibin-B\/FSH ratio in a boy treated with imatinib during puberty.","volume":"372","author":"Mariani","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"2019111902573146500_B52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-008-0251-8","article-title":"Growth deceleration in a girl treated with imatinib.","volume":"89","author":"Kimoto","year":"2009","journal-title":"Int J Hematol"},{"issue":"4","key":"2019111902573146500_B53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"issue":"3","key":"2019111902573146500_B54","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"issue":"18","key":"2019111902573146500_B55","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer"},{"issue":"7","key":"2019111902573146500_B56","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/pbc.24397","article-title":"Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis.","volume":"60","author":"Narayanan","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"21","key":"2019111902573146500_B57","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3752.3752","article-title":"Impact of treatment with tyrosine kinase inhibitors (TKIs) on blood levels of growth hormone-related parameters, testosterone, and inhibin B in juvenile rats and pediatric patients with chronic myeloid leukemia (CML) [abstract].","volume":"120","author":"Ulmer","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111902573146500_B58","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome.","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111902573146500_B59","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/CAD.0b013e328352a8fe","article-title":"A dramatic fetal outcome following transplacental transfer of dasatinib.","volume":"23","author":"Berveiller","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"3","key":"2019111902573146500_B60","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.beha.2009.09.008","article-title":"CML in pregnancy and childhood.","volume":"22","author":"Apperley","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"2019111902573146500_B61","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2013-08-283580","article-title":"How I treat leukemia during pregnancy.","volume":"123","author":"Milojkovic","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111902573146500_B62","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2605.2007.00755.x","article-title":"Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.","volume":"30","author":"Nurmio","year":"2007","journal-title":"Int J Androl"},{"issue":"3","key":"2019111902573146500_B63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2011.09.025","article-title":"Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model.","volume":"36","author":"Schultheis","year":"2012","journal-title":"Leuk Res"},{"issue":"20","key":"2019111902573146500_B64","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome.","volume":"351","author":"Seshadri","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111902573146500_B65","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMc0707841","article-title":"Primary ovarian insufficiency associated with imatinib therapy.","volume":"358","author":"Christopoulos","year":"2008","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111902573146500_B66","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid"},{"issue":"6","key":"2019111902573146500_B67","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2019111902573146500_B68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.leukres.2011.01.021","article-title":"Nilotinib cardiac toxicity: should we still be concerned?","volume":"35","author":"Atallah","year":"2011","journal-title":"Leuk Res"},{"issue":"6","key":"2019111902573146500_B69","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors.","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111902573146500_B70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111902573146500_B71","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: the new goal of therapy?","volume":"20","author":"Mahon","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10 Suppl","key":"2019111902573146500_B72","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1002\/1097-0142(19930515)71:10+<3206::AID-CNCR2820711706>3.0.CO;2-A","article-title":"Cancer in adolescents and young adults.","volume":"71","author":"Reaman","year":"1993","journal-title":"Cancer"},{"issue":"2","key":"2019111902573146500_B73","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111902573146500_B74","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamapediatrics.2014.3280","article-title":"Pragmatic trial of health care technologies to improve adherence to pediatric asthma treatment: a randomized clinical trial.","volume":"169","author":"Bender","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"5","key":"2019111902573146500_B75","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2014.06.001","article-title":"Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.","volume":"28","author":"Mathisen","year":"2014","journal-title":"Blood Rev"},{"issue":"4","key":"2019111902573146500_B76","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111902573146500_B77","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.916.916","article-title":"Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts [abstract].","volume":"120","author":"Rea","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111902573146500_B78","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111902573146500_B79","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00277-013-1769-2","article-title":"Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.","volume":"92","author":"La Ros\u00e9e","year":"2013","journal-title":"Ann Hematol"},{"issue":"3","key":"2019111902573146500_B80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.leukres.2011.09.018","article-title":"What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?","volume":"36","author":"Deininger","year":"2012","journal-title":"Leuk Res"},{"issue":"11","key":"2019111902573146500_B81","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111902573146500_B82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia.","volume":"12","author":"O\u2019Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"2019111902573146500_B83","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","article-title":"JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.","volume":"122","author":"Warsch","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111902573146500_B84","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"issue":"Suppl 2","key":"2019111902573146500_B85","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML.","volume":"94","author":"Talpaz","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111902573146500_B86","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2019111902573146500_B87","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s Oncology Group study AALL0031.","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"21","key":"2019111902573146500_B88","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2534.2534","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation in children and young adults with chronic myeloid leukemia: a CIBMTR cohort analysis [abstract].","volume":"124","author":"Chaudhury","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111902573146500_B89","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/pbc.25446","article-title":"Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia.","volume":"62","author":"Meier","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2019111902573146500_B90","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2013-05-506253","article-title":"Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy.","volume":"123","author":"Eapen","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111902573146500_B91","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I.","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin Padiatr"},{"issue":"10","key":"2019111902573146500_B92","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111902573146500_B93","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","article-title":"Stem cell transplantation for chronic myeloid leukemia in children.","volume":"102","author":"Cwynarski","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111902573146500_B94","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2009.09.022","article-title":"Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program.","volume":"16","author":"Muramatsu","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111902573146500_B95","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-03-1010","article-title":"Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study.","volume":"104","author":"Baker","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2019111902573146500_B96","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/bmt.2014.114","article-title":"New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.","volume":"49","author":"Pulsipher","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111902573146500_B97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF03006933","article-title":"Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia.","volume":"86","author":"Chen","year":"2007","journal-title":"Int J Hematol"},{"issue":"5","key":"2019111902573146500_B98","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","article-title":"Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.","volume":"15","author":"van Besien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111902573146500_B99","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.bbmt.2012.05.006","article-title":"Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.","volume":"18","author":"Law","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111902573146500_B100","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12185-012-1209-4","article-title":"Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin.","volume":"96","author":"Hatanaka","year":"2012","journal-title":"Int J Hematol"},{"issue":"12","key":"2019111902573146500_B101","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1038\/leu.2012.135","article-title":"Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.","volume":"26","author":"Baron","year":"2012","journal-title":"Leukemia"},{"issue":"25","key":"2019111902573146500_B102","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/4\/392\/1395180\/392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/4\/392\/1395180\/392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T10:14:42Z","timestamp":1599732882000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/4\/392\/35042\/Pediatric-chronic-myeloid-leukemia-is-a-unique"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,28]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-06-648667","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,28]]}}}